pf-06480605
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT01989143)
Timeline
Indications
Mechanism of action
TNFSF15 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-06480605
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05107492 | Phase 1 | Nov 19, 2021 | Pfizer |
| NCT04269538 | Phase 1 | Feb 19, 2020 | Pfizer |
| NCT04090411 | Phase 2 | Nov 22, 2019 | Pfizer |
| NCT02840721 | Phase 2 | Oct 26, 2016 | Pfizer |
| NCT01989143 | Phase 1 | Dec 1, 2013 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 5 | 2 | 2013 |
1 organizations
Page 1 / 1